Bowon Chemical's annual results show sales and profit moving in different directions. Sales rose 31.4% to KRW 52.2 billion in 2025 from KRW 39.7 billion in 2024, and operating profit rose 7.5% to KRW 5.12 billion from KRW 4.76 billion.
Because sales grew much faster than operating profit, operating margin fell from 12.0% in 2024 to 9.8% in 2025. A media report pointed to higher R&D, labor and defect-repair costs, along with raw material price increases, as pressure on margins.
Net income attributable to controlling shareholders fell 87.0% to KRW 218 million in 2025 from KRW 1.67 billion in 2024, and total net income followed the same path to KRW 218 million.
The same report said financial costs fell from KRW 3.9 billion in the first half of 2025 to KRW 900 million in the first half of 2026, easing non-operating pressure.
At end-2025, total equity was KRW 24 billion, of which controlling-shareholder equity was also KRW 24 billion, and total liabilities were KRW 46.2 billion. Operating cash flow fell from KRW 7.59 billion in 2024 to KRW 5.29 billion in 2025.
In Q1 2026, sales were KRW 15 billion and operating profit KRW 971 million, but a merger-related convertible bond cost booked below operating profit produced a controlling-shareholder net loss of KRW 1.25 billion.
Q2 sales were KRW 13.7 billion, down 8.6% from the prior quarter, operating profit was KRW 1.02 billion, up 5.5%, and controlling-shareholder net income of KRW 887 million turned the quarter into a profit.
Q3 sales were KRW 14.6 billion, up 6.7%, and operating profit was KRW 1.07 billion, up 4.5%, extending the two consecutive quarterly increases since the Q1 2026 low, while controlling-shareholder net income of KRW 498 million was down 43.9%. Controlling-shareholder net income for the last four quarters (Q1 2025 to Q4 2025) totaled KRW 218 million.